The Global Taskforce on Radiotherapy for Cancer Control (GTFRCC) was established to determine the global burden of cancer amenable to treatment with radiotherapy; the investment needed to bridge the current gaps in radiotherapy access to meet this need; and what human and financial benefits would be generated from this.
The GTFRCC found that:
Dr David Jaffray, Head of the GTFRCC Secretariat, presents on why the GTFRCC was established, how and why the aims were developed and are relevant to the global health community. David also talks through how the team reached their results, their implications for the global cancer community and next steps.
Dr Danielle Rodin runs through the investment case for radiotherapy and explores the long term costs and benefits of scaling up radiotherapy investment for high-, middle-, and low-income countries alike.
The Global Taskforce on Radiotherapy for Cancer Control (GTFRCC) concluded that radiotherapy is an important, cost effective and feasible investment for all countries. To help achieve improved access to radiotherapy by 2035 the GTFRCC identified a five-point call to action:
1. Incorporate radiotherapy into population-based cancer control plans
2. Increase radiotherapy treatment capacity
3.Train radiation oncologists, radiation technologists, and medical physicists in LMICs
4. Invest to establish radiotherapy infrastructure and training in LMICs
5. Include radiotherapy services as part of the universal health coverage plans in 80% of LMICs by 2020
Prof. Mary Gospodarowicz, GTFRCC Secretariat member and Medical Director at the Princess Margaret Cancer Centre explores the commission’s 5-point call to action.
Barton, Frommer & Shafiq (2006) Role of radiotherapy in cancer control in low-income and middle-income countries, Lancet Oncology 7(7): 584-595 [Accessed 24.04.2017] http://thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(06)70759-8.pdf
 Farmer et al. (2010) Expansion of cancer care and control in countries of low and middle income: a call to action, The Lancet 376(9747):1186-1193 [Accessed 24.04.2017] http://www.thelancet.com/article/S0140-6736(10)61152-X/abstract
 John & Ross (2010) The global economic cost of cancer: report summary [Accessed 24.04.2017] http://phrma-docs.phrma.org/sites/default/files/pdf/08-17-2010_economic_impact_study.pdf